Sinocare Inc (300298) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocare Inc (300298) has a cash flow conversion efficiency ratio of 0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥264.19 Million ≈ $38.66 Million USD) by net assets (CN¥3.67 Billion ≈ $537.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Sinocare Inc worth for the company's overall valuation and market capitalisation.
Sinocare Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Sinocare Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinocare Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocare Inc ranked by their cash flow conversion efficiency. Explore how high is Sinocare Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyient Limited
NSE:CYIENT
|
0.071x |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
0.035x |
|
Fras-le S.A
SA:FRAS3
|
0.130x |
|
Kidswant Children Products Co.Ltd.
SHE:301078
|
N/A |
|
Zillow Group Inc
NASDAQ:ZG
|
0.045x |
|
TianJin 712 Communication & Broadcasting Co Ltd
SHG:603712
|
-0.055x |
|
TTW Public Company Limited
BK:TTW
|
0.045x |
|
Zbit Semiconductor Inc. A
SHG:688416
|
N/A |
Annual Cash Flow Conversion Efficiency for Sinocare Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Sinocare Inc from 2008 to 2024. View 300298 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.77 Billion ≈ $551.61 Million |
CN¥631.29 Million ≈ $92.38 Million |
0.167x | -20.94% |
| 2023-12-31 | CN¥3.47 Billion ≈ $507.88 Million |
CN¥735.15 Million ≈ $107.57 Million |
0.212x | +40.36% |
| 2022-12-31 | CN¥3.14 Billion ≈ $460.00 Million |
CN¥474.39 Million ≈ $69.42 Million |
0.151x | -12.21% |
| 2021-12-31 | CN¥2.79 Billion ≈ $408.61 Million |
CN¥480.03 Million ≈ $70.24 Million |
0.172x | -6.63% |
| 2020-12-31 | CN¥2.74 Billion ≈ $401.11 Million |
CN¥504.64 Million ≈ $73.84 Million |
0.184x | -6.72% |
| 2019-12-31 | CN¥2.65 Billion ≈ $387.62 Million |
CN¥522.81 Million ≈ $76.50 Million |
0.197x | +62.15% |
| 2018-12-31 | CN¥2.62 Billion ≈ $383.83 Million |
CN¥319.27 Million ≈ $46.72 Million |
0.122x | -30.65% |
| 2017-12-31 | CN¥1.39 Billion ≈ $203.34 Million |
CN¥243.89 Million ≈ $35.69 Million |
0.176x | +10.25% |
| 2016-12-31 | CN¥1.28 Billion ≈ $186.99 Million |
CN¥203.42 Million ≈ $29.77 Million |
0.159x | +62.46% |
| 2015-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
CN¥121.52 Million ≈ $17.78 Million |
0.098x | -28.90% |
| 2014-12-31 | CN¥1.11 Billion ≈ $162.61 Million |
CN¥153.15 Million ≈ $22.41 Million |
0.138x | +13.95% |
| 2013-12-31 | CN¥946.01 Million ≈ $138.43 Million |
CN¥114.42 Million ≈ $16.74 Million |
0.121x | -20.83% |
| 2012-12-31 | CN¥845.18 Million ≈ $123.68 Million |
CN¥129.12 Million ≈ $18.89 Million |
0.153x | -68.09% |
| 2011-12-31 | CN¥179.51 Million ≈ $26.27 Million |
CN¥85.93 Million ≈ $12.57 Million |
0.479x | -34.81% |
| 2010-12-31 | CN¥91.35 Million ≈ $13.37 Million |
CN¥67.08 Million ≈ $9.82 Million |
0.734x | -29.18% |
| 2009-12-31 | CN¥41.49 Million ≈ $6.07 Million |
CN¥43.03 Million ≈ $6.30 Million |
1.037x | +136.80% |
| 2008-12-31 | CN¥17.42 Million ≈ $2.55 Million |
CN¥7.63 Million ≈ $1.12 Million |
0.438x | -- |
About Sinocare Inc
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People's Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic disease… Read more